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ABSTRACT: Testosterone is converted to 5 a-dihydrotestosterone
(DHT) by 5 a-reductase enzyme, which is encoded by the SRD5A2
gene. DHT is the main androgen responsible for prostate growth. We
have analyzed the complete coding region of the SRD5A2 gene in 87
histologically confirmed prostate cancer (PC) patients, 40 benign
prostatic hyperplasia (BPH) cases, and 96 control samples from
southern parts of India. The study revealed the A49T site to be
monomorphic, the V89L site to be highly polymorphic, and the (TA)n
repeat site to be polymorphic with only 2 alleles in our populations.
The distribution of V89L alleles between PC cases and controls was
not significantly different; however, (TA)9 alleles distributed differ-
ently between the 2 groups. BPH cases exhibited alleles similar to
controls at all polymorphic sites. The sequencing of the whole coding
region did not reveal any other known or novel polymorphism in this
gene. Our study emphasizes that the (TA)9 allele might confer
certain PC risk but that A49T and V89L polymorphisms do not confer
PC risk in South Indian men.
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P rostate cancer (PC) is the most common form ofcancer in males and the second most common cause
of cancer leading to death (Jemal et al, 2008). Benign
prostatic hyperplasia (BPH) is the most common
urological condition in elderly men. BPH is not
associated with PC; however, men can have both PC
and BPH (Ziada et al, 1999). The incidence of PC
increased in the American population in the late 1980s
and early 1990s. A similar increase has also been
observed in low-risk countries like India (Srinivas et
al, 1995). The occurrence of PC demonstrates familial
aggregation, with a 2- to 4-fold increased risk among
men reporting PC in a father or brother after adjustment
for age and dietary factors (Heinlein and Chang, 2004).
Androgens (testosterone and 5 a-dihydrotestosterone)
are actively involved in prostate development (Heinlein
and Chang, 2004). Approximately 80%–90% of prostate
cancers are dependent on androgens at initial diagnosis,
and endocrine therapy of PC is directed toward the
reduction of serum androgens and inhibition of andro-
gen receptor (AR) (van der Kwast et al, 1991).
Therefore, the AR gene has been studied extensively in
PC, and polymorphisms in the AR gene have been
associated with PC risk (for review see Rajender et al,
2007).
Testosterone, after entering into the target cells, is
converted to the more potent androgen dihydrotestos-
terone (DHT) by the action of the enzyme, 5 a-reductase
(Wilbert et al, 1983; Coffey, 1993). DHT is mainly
responsible for prostate growth, and it has been
demonstrated that the tissue DHT level is a useful
marker in predicting the clinical response of prostate
cancer to anti-androgen therapy (Geller et al, 1984). The
levels of DHT and resulting androgen action vary
among different individuals depending on the activity of
5 a-reductase. Ross et al (1992) demonstrated that
young Japanese men have lower 5 a-reductase activity
than young Caucasian American and African American
men. Similarly, Wu et al (1995) reported that the
DHT:testosterone ratio was highest in African Ameri-
cans, intermediate in Caucasians, and lowest in Asian
Americans, corresponding to the respective risk of
developing PC in these groups. Taking the above into
consideration, it has been hypothesized in several studies
that the polymorphisms in the SRD5A2 gene could
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affect PC risk (Kantoff et al, 1997; Lunn et al, 1999;
Hsing et al, 2001; Latil et al, 2001).
The human SRD5A2 gene, mapped on chromosome 2
(2p23), has 5 exons and 4 introns and encodes the
enzyme 5 a-reductase, expressed in androgen-dependent
tissues (Thigpen et al, 1993). A number of mutations/
polymorphisms have been identified in the SRD5A2
gene; however, A49T, V89L, and (TA)n repeat poly-
morphisms are the most frequent. Most of the study till
date have analyzed only A49T, V89L single-nucleotide
polymorphisms, and (TA)n polymorphic repeat regions.
Controversies exist regarding the association of these
polymorphisms with PC risk (Ntais et al, 2003). The
meta-analyses are of immense use in such situations to
resolve controversies; however, the bias in the publica-
tion of the studies showing positive correlation rather
than no correlation might make the meta-analysis less
transparent. To assess the correlation more judiciously,
the studies finding no significant correlation of the
polymorphism(s) with the disorder should also be
brought forward, and an effort should be made to
generate data on various populations of the world. This
study is such an effort. We analyzed the SRD5A2 gene
for mutations/polymorphisms in Indian PC patients. To
the best of our knowledge, no previous study has
analyzed the full coding region of the SRD5A2 gene
among Indian prostate cancer patients. We have
undertaken sequencing of the full coding region and a
part of the 39 UTR region encompassing the (TA)n
repeat of the SRD5A2 gene to understand the role of
SRD5A2 polymorphisms in disease risk and to assess
the racial and ethnic differences from other populations
of the world (Table 1).
Materials and Methods
Subjects
The study included 87 histologically confirmed PC cases, 40
BPH patients, and 96 male control subjects from the southern
parts of India. The control comprised healthy individuals with
normal serum PSA levels of 4 ng/mL of blood or less
(reference level, ,4 ng/mL), with no previous history of
cancer, which was confirmed by digital rectal examination.
BPH patients had normal serum PSA levels (#4 ng/mL) and
were examined by digital rectal examination to confirm
enlarged prostate. However, no histology could be done for
the BPH group because of the lack of biopsy. All cases and
controls were enrolled under informed written consent. The
patients and controls were enrolled from a population with the
same ethnic origin. Relevant clinical and pathological data
were collected for all the patients. In PC patients age ranged
from 45 to 98 years, with a mean age of 67.5 years; 55–77 years
with a mean of 65.5 years in BPH patients, and 50–81 years
with a mean of 66.5 years in normal healthy controls.
Pathological grading of the tumors by Gleason scores was
obtained, and the patients were classified as low grade if their
Gleason scores were less than 7 and high grade if their Gleason
scores were greater than or equal to 7. The Gleason score was
less than 7 in 48 patients and greater than or equal to 7 in 39
patients. The study was approved by the ethical committee of
the Institute.
Table 1. Few earlier studies analyzing polymorphisms in the SRD5A2 gene in relation to prostate cancer (PC) risk
Study Ethnicity
Association With PC Risk
A49T V89L (TA)n
Kantoff et al, 1997 American Not analyzed Not analyzed No association
Lunn et al, 1999 American Not analyzed No association Not analyzed
Febbo et al, 1999 American Not analyzed No association Not analyzed
Yamada et al, 2001 Japanese No T allele No association Not analyzed
Hsing et al, 2001 Chinese No T allele No association No association
Cussenot et al, 2001 French Not analyzed Leu/Leu genotype associated Not analyzed
Latil et al, 2001 French No association No association No association
Mononen et al, 2001 Finnish No association Not analyzed Not analyzed
Soderstrom et al, 2002 Swedish No association No association Not analyzed
Giwercman et al, 2005 Sweden T variant associated Leu/Leu genotype associated Not analyzed
Salam et al, 2005 Asian, Hispanic, Caucasian,
African American
No association Val/Val, Val/Leu genotypes
associated, association
stronger in Hispanics
Not analyzed
Hayes et al, 2007 Australian A variant associated No association Not analyzed
Sobti et al, 2006 Indian Not analyzed No association Not analyzed
Onen et al, 2007 Turkey No T allele No association Not analyzed
Present study Indian No T allele No association Longer alleles
associated
Abbreviations: Leu, leucine; Val, valine.
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Genetic Analysis of SRD5A2 Gene
Genomic DNA was isolated from peripheral blood lympho-
cytes by the method described in our earlier study (Thangaraj
et al, 2002). The primers used for polymerase chain reaction
(PCR) amplification of the SRD5A2 gene, including intron/
exon junctions, were designed with GeneTool software and
synthesized with the use of a 394 DNA/RNA oligosynthesizer
(Applied Biosystems, Foster City, California). Conditions for
PCR amplification along with primer sequences for each exon
are detailed in Table 2. The PCR products were sequenced
directly by the dideoxy cycle sequencing chain termination
method (Big Dye V3.1, Applied Biosystems) on an ABI 3730
DNA analyzer (Thangaraj et al, 2003). Sequence editing and
multiple alignments were carried out with AutoAssembler
software (Applied Biosystems). The sequencing signal for the
V89L polymorphism was not clear at the polymorphic site
despite repeated efforts; therefore, this polymorphism was
typed by PCR restriction fragment length polymorphism
(PCR-RFLP). The restriction reaction included a 10-mL PCR
product, 2 units of RsaI restriction enzyme, 10 mL of
restriction buffer, and incubation at 37uC for 1 hour. After
restriction digestion, the reaction mixture was run on 10%
PAGE to see the banding pattern. For distinguishing the
homozygous and heterozygous genotypes at the (TA)9 repeat,
we amplified this region with the FAM (carboxyfluorescein)-
labeled forward primer (Table 2) and genotyped it with 3730
DNA analyzer. For genotyping, 3.0 mL of PCR product was
mixed with 0.3 mL of LIZ size standard (Applied Biosystems)
and 6.7 mL of Hi-Di formamide (Applied Biosystems). Before
running on the DNA analyzer, the mixture was heated to 95uC
for 5 minutes, followed by cooling on ice for 5 minutes.
Statistical Analyses
We calculated the allelic percentages for SRD5A2 polymor-
phisms and analyzed them for differences between cases and
controls. Because it is known that the SRD5A2 allele with
valine (Val) at the V89L polymorphic site confers high activity
to the enzyme compared with the allele with leucine (Leu)
(Makridakis et al, 2000), the genotypes at this site were named
high-activity (Val/Val) and low-activity (Val/Leu and Leu/Leu)
genotypes. The high- and low-activity genotypes were analyzed
for differences between cases and controls. The test was
performed for PC vs controls and BPH vs controls,
independently. We used the chi-square (x2) test to calculate
the significance of differences between cases and controls. Chi-
square values were calculated with the online Vassar Stats
Calculator (http://faculty.vassar.edu/lowry/VassarStats.html).
Two-sided P values of less than .05 were taken to be
significant. We analyzed the frequency distribution of various
genotypes at the V89L polymorphic site with respect to various
clinical parameters using SPSS software (version 11; SPSS Inc,
Chicago, Illinois). Furthermore, different alleles at the V89L
and (TA)n polymorphic sites were examined for linkage
disequilibrium in both the cases and the controls.
Results
We did not observe any polymorphism at the A49T
polymorphic site (Table 3). PC, BPH, and control
samples invariably had the wild-type allele (A) at this
site. The V89L site was highly polymorphic (Figure 1);
however, the differences in the frequency distribution of
various alleles/genotypes at this site were not significant
between PC cases and controls or BPH and controls
Table 2. Polymerase chain reaction (PCR) primers used for amplification of the coding regions of the SRD5A2 gene
Primer Symbol Primer Sequences, 59–39 PCR Conditions Product Size, bp
SRD 1 GGGGGCGGACACGGGTGGC
GGCAGAAGAGGCCCAGAAGTAC
94uC, 12 min; (94uC, 45 s; 58uC, 45 s; 72uC,
1 min) 6 35 cycles; 72uC, 10 min
363
SRD 2 CCGGCGGCTACCCGCCTGCCAG
CTAGAGAGTTGACAAGCGGCTGCGGC
94uC, 12 min; (94uC, 45 s; 58uC, 45 s; 72uC,
1 min) 6 30 cycles; 72uC, 10 min
361
SRD 3 TGGGTTAAGGCGAAATGGCAGAG
GGTGCAGGGAGCCAGGAAAAGA
94uC, 12 min; (94uC, 45 s; 60uC, 45 s; 72uC,
1 min) 6 30 cycles; 72uC, 10 min
607
SRD 4 CCCCATTCAGGACCAGGACTCA
TGGCCAAGCATTCAGCATCATTT
94uC, 12 min; (94uC, 45 s; 58uC, 45 s; 72uC,
1 min) 6 30 cycles; 72uC, 10 min
644
SRD 5 GCCCCACATTTGTTCTTGCTG
CAAGCCCAGCAAGTCAGAATATG
94uC, 12 min; (94uC, 45 s; 58uC, 45 s; 72uC,
1 min) 6 30 cycles; 72uC, 10 min
420
SRD6 GGCTGTGGGAAGGAGAAATAAGA
GCTTCAGTTGGGGATCAGGATAG
94uC, 12 min; (94uC, 1 min; 58uC, 45 s; 72uC, 1:
30 min) 6 30 cycles; 72uC, 10 min
439
Table 3. Comparison of the percentage of various SRD5A2
alleles between cases and controls
Polymorphic
Site Allele
PC Cases,
%
BPH Patients,
%
Controls,
%
A49T A 100 100 100
T 0 0 0
V89L V 51.15 51.30 52.08
L 48.85 48.70 47.92
(TA)n repeat (TA)0 97.7 100 100
(TA)9 2.3 0 0
(TA)18 0 0 0
Abbreviations: A, alanine (wild-type alleles); BPH, benign prostatic
hyperplasia; L, leucine; PC, prostate cancer; T, threonine; V, valine
(wild-type allele).
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(Table 3). For genotype analyses, the Val/Val genotype
was considered to be a high-activity genotype, whereas
Val/Leu and Leu/Leu were considered to be low-activity
genotypes. We did not find any difference between cases
and controls in the distribution of high- and low-activity
genotypes (Table 4). At the (TA)n repeat site, we
observed the (TA)0 allele to be the most common in
both the cases (97.7%) and the controls (100%), whereas
(TA)9 occurred at a very low frequency (2.3%) among
the PC cases only (Table 3). PC cases exhibited all 3
possible genotypes at the (TA)n site, with a maximum
frequency (96.55%) of (TA)0/(TA)0, a low frequency
(2.3%) of (TA)0/(TA)9, and an even lower frequency
(1.15%) of (TA)9/(TA)9 (Table 4). BPH and control
samples invariably presented with the (TA)0/(TA)0
genotype, with the other 2 genotypes being absent.
Although the genotypes with longer (TA)n alleles were
not so common in the cases, its absence from the control
and BPH groups might indicate disease risk associated
with longer alleles in a subpopulation of Indian men.
Haplotype analyses indicated that the presence of the
(TA)9 repeat did not preferentially associate with Val/
Val, Val/Leu, or Leu/Leu genotypes at the V89L site,
indicating the absence of linkage disequilibrium between
the 2 polymorphic sites. Correlation analyses showed
that the presence of the Val/Leu and Leu/Leu genotypes
at this site correlated with higher levels of PSA
compared with the Val/Val genotype (r 5 .301, P 5
.005; Figure 2). No other parameter correlated positive-
ly or negatively with the V89L polymorphic site. BPH
cases possessed alleles and genotypes similar to the
control samples at all the 3 polymorphic sites.
Discussion
Testosterone and its metabolite DHT are crucial for
growth and development of prostate gland. The research
Figure 1. Restriction fragment length polymorphism (RFLP) analysis
for V89L polymorphism. Lane 1 (marked M): 100-bp DNA ladder;
lane 2 (marked 1): Val/Val; lane 3 (marked 2): Leu/Leu; lane 4
(marked 3): Val/Leu. The presence or absence of 120- and 100-bp
fragments discriminates among the 3 possible genotypes at this site,
whereas the fragments of 404 and 168 bp are common in the
3 samples.
Table 4. Comparison of various SRD5A2 genotypes between cases and controls. The respective percentage of each genotype
is indicated in parenthesesa
A/T Polymorphism
A/A A/T and T/T TT x2 P value
PC 87 0 0 . . . . . .
BPH 40 0 0 . . . . . .
Controls 96 0 0 . . . . . .
V/L Polymorphism
V/V V/L L/L x2 P value
PC 25 (28.74) 39 (44.83) 23 (26.44) 0 1
BPH 12 (30) 16 (40) 12 (30) .03 .86
Controls 29 (30.20) 42 (43.75) 25 (26.04) . . . . . .
(TA)n Polymorphism
(TA)0/(TA)0 (TA)0/(TA)9 TA)9/(TA)9
PC 84 (96.55) 2 (2.30) 1 (1.15) . . . . . .
BPH 40 (100) 0 (0) 0 (0) . . . . . .
Controls 96 (100) 0 (0) 0 (0) . . . . . .
Abbreviations: A, alanine (wild-type alleles); BPH, benign prostatic hyperplasia; L, leucine; PC, prostate cancer; T, threonine; V, valine (wild-
type allele).
a The x2 and the respective P values for the V89L polymorphism were calculated for PC cases vs control and for BPH cases vs controls
separately. For this purpose, the 3 genotypes at this site were classified into 2 groups for both the cases and the controls: high activity (Val/Val)
and low activity (Val/Leu and Leu/Leu).
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on PC has focused mainly on the genes related to
androgen action. In this study, we have sequenced the
entire coding region and 39 UTR region encompassing
the (TA)n repeat of the SRD5A2 gene in 87 PC cases, 40
BPH cases, and 96 control samples. Most of the studies
on the SRD5A2 gene in PC have focused only on these 3
polymorphisms (A49T, V89L, and [TA]n repeat). We
have for the first time analyzed the entire coding
sequence. The study revealed no polymorphism at the
A49T locus. Differences in the distribution of (TA)n
alleles but not V89L alleles were observed between the
cases and the controls. Earlier studies on these
polymorphisms in SRD5A2 have shown contradictory
results. However, a meta-analysis has shown no
significant association of any of these polymorphisms
with prostate cancer susceptibility (Ntais et al, 2003).
More studies might help to resolve the controversy
regarding the association of genetic variations in the
SRD5A2 gene with PC risk.
We observed no polymorphism at the A49T locus. All
PC, BPH, and control samples had A at this site. A49T
has been one of the most commonly studied polymor-
phisms in the SRD5A2 gene. The A49T variant (Ala 49
Thr substitution) has been linked to pathological
characteristics of PC (Jaffe et al, 2000). It increases the
activity of the steroid 5-a-reductase enzyme by 5-fold.
The T variant has been found to be more prevalent in
Caucasians (3.5%) than African Americans, Asians, or
Hispanics (Jaffe et al, 2000). An A49T amino acid
substitution increased the risk of clinically significant
disease by 7.2-fold in African American men (95%
confidence interval [CI], 2.17–27.91; P 5 .001) and 3.6-
fold in Hispanic men (CI, 1.09–12.27; P 5 .04). The
polymorphism was reported to increase PC risk, and the
mutant enzyme had a higher in vitro Vmax than the
normal enzyme (9.9 compared with 1.9 nmol -
min21 mg21; Makridakis et al, 1999). This polymor-
phism has been reported among Caucasian men and
Asians but showed no association with PC risk (Latil et
al, 2001; Mononen et al, 2001; Soderstrom et al, 2002).
Earlier studies on Japanese (Yamada et al, 2001) and
Chinese men (Hsing et al, 2001) also demonstrated
monomorphism at the A49T locus. Taking our results
into account, it appears that Asian or, more narrowly,
South Asians have similar alleles (A) at this locus, which
might signify their genetic affinities. Indian men thus
carry a low-risk allele at this locus compared with
Caucasians, African Americans, and Hispanics. Never-
theless, it is very important to generate similar data for
other Indian and South Asian populations to strengthen
or refute the above statement.
We observed the V89L site to be highly polymorphic,
but no significant difference was observed between PC
cases and controls or BPH and control samples. The
V89L substitution occurs at a frequency of 8.5% in
Caucasians, 2.5% in African Americans, and 28% in
Taiwanese men (Nwosu et al, 2001). The V89L
polymorphism is more common than the A49T, at
around 30% frequency (Febbo et al, 1999; Jaffe et al,
2000; Makridakis et al, 2000). It has been shown that the
distribution of V89L genotypes parallels the patterns of
PC incidence in high- and low-risk populations, with an
Leu/Leu genotype prevalence of 22%–25% among
Asians and of only about 4% among Caucasian and
African Americans, and a Val/Val genotype prevalence
of 27%–29% among Asians and about 58% among
African and Caucasian Americans (Makridakis et al,
1999; Ross et al, 1992; Yamada et al, 2001). Similarly,
Nam et al (2001) have claimed a 3.3-fold increased risk
of disease recurrence with the Val/Val and Val/Leu
genotypes in Canadian populations. The results of the
above studies are supported by in vitro studies showing
that, compared with the Val/Val genotype, the Leu/Leu
genotype confers a 42% reduction in 5 a-reductase
enzymatic activity (Makridakis et al, 2000). Conversely,
other studies on French (Cussenot et al, 2007) and
Swedish populations (Giwercman et al, 2005) reported
that the Leu/Leu genotype is associated with PC risk.
This polymorphism has not found significant associa-
tion with PC risk among Caucasian men (Febbo et al,
1999; Lunn et al, 1999) and in Japanese men (Yamada et
al, 2001). Similar to the above studies, we did not
observe any difference in the distribution of V89L
alleles/genotypes between cases and controls. An earlier
study of a North Indian population also reported no
Figure 2. Bar graph showing association of various parameters (PSA
level and Gleason score) with different genotypes at V89L
polymorphic site. Y-axis shows the percentage of PC cases.
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association of the V89L polymorphism with PC risk
(Sobti et al, 2006). In all the studies on South Asian
populations, no association was detected with the V89L
polymorphism; however, contradicting results are evi-
dent from studies on other populations (Table 1).
The (TA)n repeat site has been relatively less studied.
Since identification of the (TA)n repeat polymorphism, 3
major alleles have been reported—(TA)0, (TA)9, and
(TA)18—with (TA)0 being the most common in most of
the populations (Akalu et al, 1999). The observation
that the rare (TA)18 allele is limited to African American
populations (Reichardt et al, 1995), who have a higher
rate of prostate cancer than Asian American or
Caucasian men (Parkin et al, 1997), suggests that a
longer allele might be associated with increased enzyme
activity. The relevance of the (TA)n marker in prostate
cancer is further supported by the finding that 56% of 30
prostate tumors possessed somatic mutations at this
locus (Akalu et al, 1999). Thus, polymorphism at this
locus might increase the risk of prostate cancer. We
observed the (TA)9 allele in 2.3% of the cases, although
the frequency was too low to lay a strong association
with PC risk (Table 3). In contrast, certain case control
studies in Caucasian and Asian men have not found the
(TA)9 variant to be associated with an increased
prostate cancer risk (Kantoff et al, 1997; Hsing et al,
2001; Latil et al, 2001). In a few other studies, the longer
(TA)n was not found to be associated with increased
prostate cancer risk (Kantoff et al, 1997; Hsing et al,
2001; Latil et al, 2001). The longest allele, (TA)18, was
found exclusively in African Americans, who are at
increased risk of prostate cancer (Reichardt et al, 1995).
In accordance with the above observation, the (TA)18
allele was absent from our cases as well controls.
A49T and V89L polymorphisms are present in the
coding regions of the SRD5A2 gene and hence affect the
enzyme activity by amino acid substitutions. But the
(TA)n repeat is located in the 39 UTR of the SRD5A2
gene; therefore, it is unlikely to affect the structure or
function of the resulting protein. However, it has been
proposed that this polymorphism might influence
regulation of 5 a-reductase enzyme production (Reich-
ardt et al, 1995; Kantoff et al, 1997), probably by
altering mRNA stability (Zubiaga et al, 1995). As a
result, this polymorphism might alter DHT levels and
consequently the risk of developing PC (Reichardt et al,
1995). However, currently no study has addressed length
of the (TA)n repeat in concert with intraprostatic levels
of DHT. Out of 14 studies listed in Table 1, only 5
(35.71%) have analyzed the A49T polymorphism, 12
(85.71%) have analyzed the V89L polymorphism, and
only 3 (21.43%) have analyzed the (TA)n repeat. Only 2
studies (14.28%) have analyzed all 3 polymorphisms
discussed above. Contrasting results for the A49T and
V89L polymorphisms in our populations and the PC
risk associated with longer (TA)n alleles emphasize the
need to analyze the (TA)n repeat polymorphism in
addition to A49T and V89L polymorphisms in further
studies on this gene. Nevertheless, no study to date has
analyzed the effect of the environment, if any.
Our study revealed monomorphism at the A49T locus
and polymorphisms at the V89L and (TA)n sites.
Inference on the basis of other populations indicates
that our population carries a low-risk allele at the A49T
site. Different variants at the V89L locus were almost
equally frequent and conferred no PC risk. We found
that the presence of the (TA)9 allele might confer a PC
risk; however, the difference was small. As observed in
other populations, the (TA)18 allele was absent from our
samples, which could be for ethnic reasons. Sequence
analysis of the whole coding region of the SRD5A2 gene
did not reveal any other known or novel polymorphism.
Therefore, it seems that V89L and (TA)n are the major
polymorphic sites in the SRD5A2 gene in our popula-
tion. The allelic variations in BPH were similar to
controls at the (TA)n site, but the absence of longer
(TA)n alleles in BPH cases cannot be ascertained given
the lesser number of these cases in this study. The
limitation of the sample size and certain variations in the
percentage of various alleles on increasing the sample
size cannot be denied. Our study emphasizes that A49T
and V89L are not useful markers to use to estimate PC
risk in Indian men, but the (TA)9 repeat might be
associated with PC risk to a certain extent; however, the
low frequency limits any diagnostic value of this
polymorphism. Therefore, it is clear from our study
that the polymorphic status of the SRD5A2 gene is
entirely different in Indian populations. We strongly
suggest analysis of the SRD5A2 gene in more popula-
tions to clearly understand the conflicting observations
regarding the association of A49T, V89L, and the (TA)n
repeat polymorphisms with PC risk.
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